|
|
|
| Epidemiological investigation of a case with SARS-CoV-2 infection associated with overseas countries at an international harbor |
| ZHANG Dongliang1, YI Bo2, CHEN Yi1, HU Qunxiong3, LING Feng4, MA Xiao2, LEI Song1, DONG Hongjun2, NI Hongxia2, MAO Yang2, LI Qiaofang3, CHEN Yaorong3, LU Ye4, GONG Zhenyu4, CAI Jian4, CHEN Zhiping4, LÜ Jun5, XU Guozhang2
|
1. Department of Communicable Disease Control and Prevention, Ningbo Center for Disease Control and Prevention, Ningbo, Zhejiang 315010, China;
2. Ningbo Center for Disease Control and Prevention, Ningbo, Zhejiang 315010, China;
3. Beilun Center for Disease Control and Prevention, Ningbo, Zhejiang 315800, China;
4. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China;
5. Peking University, Beijing 100191, China |
|
|
|
|
Abstract Objective To investigate the origin of infection and risk factors of a case with SARS-CoV-2 infection associated with overseas countries in the Ningbo-Zhoushan Port, Zhejiang Province, so as to provide the evidence for improving the COVID-19 control measures at ports. Methods Ningbo Center for Disease Control and Prevention ( CDC ) and Beilun CDC conducted case finding and epidemiological surveys immediately after being informed. The general information, history of vaccination and the travel during the latest 14 days were collected from the positive case, and all close contacts were tracked. Saliva samples were collected for SARS-CoV-2 nucleic acid testing and whole-genome sequencing, and the sequencing results were aligned with the GISAID's EpiCoV database. The origin of infection and transmission route of the positive case was investigated. Results A case was identified positive for SARS-CoV-2 nucleic acid during company M's routine screening in the Ningbo-Zhoushan Port on August 10, 2021, and was confirmed positive for SARS-CoV-2 nucleic acid by Beilun CDC and Ningbo CDC on August 11. Whole-genome sequencing showed SARS-CoV-2 B.1.617.2 ( Delta ) variant, which shared the highest homology with the virus sequence uploaded by Russia on June, 2021 ( Russia/MOW-RII-MH27356S/2021 ). The case was a bundling worker for overseas container ships, and reported communicated with foreign boatmen and contacted materials without protected interventions on the SINOKOR AKITA Container Ship between August 4 and 5, 2021. This ship anchored at Vladivostok, Russia from July 27 to 29, anchored at Ningbo Harbor on August 4, and departed on August 5. Then, 11 boatmen from this ship were tested positive for SARS-CoV-2 nucleic acid on August 8. One asymptomatic case was reported in this epidemic; 254 close contacts and 617 secondary close contacts were identified, and all were tested negative for SARS-CoV-2 nucleic acid. No new cases with SARS-CoV-2 infections were detected until August 25, 2021, and the emergency response was therefore terminated. Conclusions The infection was a sporadic COVID-19 epidemic associated with overseas countries, which was caused by Delta variant infection through contacts with foreign boatmen or materials by a bundling worker in Ningbo-Zhoushan Port; fortunately, no epidemic spread occurred. Intensified closed-loop management and increased frequency of SARS-CoV-2 nucleic acid test among high-risk populations, and improving the precision and rapid emergency treatment of COVID-19 epidemics are required for the containment of COVID-19 at ports.
|
|
Received: 08 February 2022
Revised: 02 March 2022
Published: 13 April 2022
|
|
|
|
|
|
[1] 戚小华,刘碧瑶,王臻,等.浙江省境外输入新型冠状病毒肺炎病例特征[J].预防医学,2021,33(6):541-544.
QI X H,LIU B Y,WANG Z,et al.The characteristics of imported COVID-19 cases from abroad to Zhejiang Province[J].Prev Med,2021,33(6):541-544.
[2] BAL A,DESTRAS G,GAYMARD A,et al. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70,France,August to December2020[J/OL]. Euro Surveill,2021,26(3)[2022-03-02].https://doi.org/10.2807/1560-7917.ES.2021.26.3.2100008.
[3] FEDER K A,PEARLOWITZ M,GOODE A,et al.Linked clusters of SARS-CoV-2 variant B.1.351-Maryland, January-February 2021[J]. MMWR,2021,70(17):627-631.
[4] CHEN J,WANG R,WANG M,et al.Mutations strengthened SARS-CoV-2 infectivity[J]. J Mol Biol,2020,432(19):5212-5226.
[5] GALLOWAY S E,PAUL P,MACCANNELL D R,et al.Emergence of SARS-CoV-2 B.1.1.7 lineage-United States,December 29,2020-January 12,2021[J]. MMWR,2021,70(3):95-99.
[6] 史庆丰,高晓东,胡必杰. Delta新冠病毒变异株的特性及流行现状与防控研究进展[J/OL].中华医院感染性杂志,2021[2022-03-02].http://www.cnki.com.cn/Article/CJFDTotal-ZHYY20210707000.htm.DOI:10.11816/cn.ni.2021-211664.
SHI Q F,GAO X D,HU B J. Research progress on characteristics,epidemiology and control measure of SARS-COV-2 Delta VOC[J/OL].Chin J Nosocomiol,2021[2022-03-02].http://www.cnki.com.cn/Article/CJFDTotal-ZHYY20210707000.htm.DOI:10.11816/cn.ni.2021-211664.
[7] 杜敏,刘民,刘珏.新型冠状病毒Delta变异株的流行病学特征及防控研究进展[J].中华流行病学杂志,2021,42(10):1774-1779.
DU M,LIU M,LIU J.Progress in research of epidemiologic feature and control of SARS-CoV-2 Delta variant[J].Chin J Epidemiol,2021,42(10):1774-1779.
[8] CHOUDHARY J,DHEEMAN S,SHARMA V,et al. Insights of severe acute respiratory syndrome coronavirus(SARS-CoV-2) pandemic:a current review[J/OL].Biol Proced Online,2021,23[2022-03-02].https://doi.org/10.1186/s12575-020-00141-5.
[9] 国务院应对新型冠状病毒肺炎疫情联防联控机制综合组.关于印发新型冠状病毒肺炎防控方案(第八版)的通知[EB/OL].(2021-05-11)[2022-03-02].http://www.gov.cn/xinwen/2021-05/14/content_5606469.htm.
[10] 中华人民共和国国家卫生健康委员会办公厅国家中医药管理局办公室.关于印发新型冠状病毒肺炎诊疗方案(试行第八版修订版)的通知[EB/OL].(2021-04-14)[2022-03-02].http://www.gov.cn/zhengce/zhengceku/2021-04/15/content_5599795.htm.
[11] 国务院应对新型冠状病毒肺炎疫情联防联控机制综合组.新冠肺炎聚集性疫情处置指南(修订版)[EB/OL].(2021-09-02)[2022-03-02].https://www.thepaper.cn/newsDetail_forward_14335437.
[12] 朱瑶,韦意娜,孙畅,等. 新型冠状病毒肺炎疫苗研究进展[J]. 预防医学,2021,33(2):143-148.
ZHU Y,WEI Y N,SUN C,et al.Development of vaccines against COVID-19[J]. Prev Med,2021,33(2):143-148.
[13] 徐娜妮,胡小炜,李海燕,等.接种新型冠状病毒灭活疫苗血清抗体水平分析[J].预防医学,2022,34(1):33-37.
XU N N,HU X W,LI H Y,et al.Detection of serum antibody levels after inoculation of an inactivated SARS-CoV-2 vaccine[J].Prev Med,2022,34(1):33-37.
[14] 陈恩富. 疫苗时代新型冠状病毒肺炎疫情防控策略[J].预防医学,2021,33(3):221-225.
CHEN E F.Prevention and control strategy of COVID-19 in the vaccine era[J].Prev Med,2021,33(3):221-225.
[15] 孙烨祥,吕筠,沈鹏,等.健康医疗大数据驱动下的疾病防控新模式[J].中华流行病学杂志,2021,42(8):1325-1329.
SUN Y X,LÜ J,SHEN P,et al.A new model for disease control and prevention driven by big data in healthcare[J]. Chin J Epidemiol,2021,42(8):1325-1329. |
|
|
|
